Avelos Therapeutics
Wednesday, June 05, 2024
Oncology
Company Presentation Theater 1
- Avelos is a cutting-edge science based oncology drug development company,
particularly focusing on small molecule drugs for novel targets in the areas of synthetic lethality,
DNA damage repair and cell cycle.
- The company was founded in Sep. 2021, and is headquartered in Seoul.
- The founding members include Young-Whan Park (ex-Merck), Soongyu Choi (ex-Bayer),
Kangsik Yun (ex-National Oncoventure), who have strong expertise and networks
in new drug discovery and development.
- Currently, Avelos has 4 oncology drug programs.
AVS1001, the first-in-class DNA damage repair & cell cycle inhibitor program, is in IND enabling stage,
the others are in lead optimization stage.
- The company closed a $8 million Series A financing in 2022, and Series B financing is ongoing.
.png)
Company Website:
http://www.avelostx.com
Lead Product in Development:
- AVS1001 : Oncology, NCE, Cell cycle and DNA Damage Response target (preclinical)
- AVS1002 : Oncology, NCE, DNA Damage Response target (Discovery)
- AVS1003 : Oncology, NCE, DNA Damage Response target (Discovery)
- AVS1004 : Oncology, NCE, DNA Damage Response target (Discovery)
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4 oncology drug products
Company HQ City
Seoul
Company HQ State
Seoul
Company HQ Country
Korea, Republic of
CEO/Top Company Official
- CEO : Dr. Young-Whan Park
- CTO : Dr. Soongyu Choi
- Head of BD : Mr. Kangsik Yun
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())